Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually

Thailand and GHIT Fund join forces to tackle infectious diseases

The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules

ImmunityBio responds to FDA concerns over promotional content

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals

The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701